Kyowa Kirin Co., Ltd.
Stock Price Chart
2026/03/02 UpdatedPrice Trend
2026/03/02 UpdatedPrice & Trading Details
2026/03/02 UpdatedPRICE
TRADING
Analyst Recommendations 10 analysts
Updated 2026/03/01Shareholder Composition
Updated 2026/03/01Top Mutual Funds / ETFs
Updated 2026/03/01Major Holders
Updated 2026/03/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
3.4M | -0.77% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
2.2M | +2.37% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
1.6M | 0.00% | |
|
Fidelity Concord Street Trust-Fidelity International Index Fund
|
839.9K | +0.86% | |
|
iShares, Inc.-iShares MSCI Japan ETF
|
811.9K | -1.01% | |
|
iShares Trust-iShares MSCI EAFE ETF
|
808.0K | +1.10% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Boston Common Asset Management, LLC
|
12.5K | -98.19% | |
|
Pacer Advisors, Inc.
|
1.9K | -3.54% |
Dividend History 4Years Growth
Updated 2026/03/01| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥62 | +6.9% |
| 2024 | ¥58 | +3.6% |
| 2023 | ¥56 | +9.8% |
| 2022 | ¥51 | +10.9% |
| 2021 | ¥46 | - |
Financial Performance
2026/03/01 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥352,246M | ¥398,371M | ¥442,233M | ¥495,558M |
| Gross Profit | ¥264,398M | ¥311,455M | ¥331,026M | ¥362,947M |
| Operating Income | ¥61,111M | ¥82,374M | ¥95,842M | ¥91,866M |
| Pretax Income | ¥61,167M | ¥68,660M | ¥97,436M | ¥90,991M |
| Net Income | ¥52,347M | ¥53,573M | ¥81,188M | ¥59,870M |
| EPS | ¥97.39 | ¥99.66 | ¥151.01 | ¥113.06 |
| Operating Margin | 17.35% | 20.68% | 21.67% | 18.54% |
| Balance Sheet | ||||
| Total Assets | ¥921,872M | ¥939,881M | ¥1,025,942M | ¥1,067,363M |
| Total Equity | ¥737,162M | ¥762,826M | ¥836,418M | ¥850,811M |
| Total Liabilities | ¥184,710M | ¥177,055M | ¥189,524M | ¥216,552M |
| Cash | ¥335,084M | ¥339,194M | ¥403,083M | ¥244,681M |
| Interest-bearing Debt | - | - | - | - |
| Equity Ratio | 79.96% | 81.16% | 81.53% | 79.71% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | ¥86,546M | ¥48,672M | ¥115,552M | ¥67,884M |
| Investing CF | -¥11,362M | -¥17,185M | -¥20,381M | -¥142,389M |
| Financing CF | -¥28,446M | -¥29,032M | -¥32,535M | -¥84,697M |
| Free CF | ¥66,780M | ¥20,006M | ¥82,700M | -¥37,384M |
| Efficiency | ||||
| ROE | 7.10% | 7.02% | 9.71% | 7.04% |
| ROA | 5.68% | 5.70% | 7.91% | 5.61% |
Latest IR Information
-
(Correction) Partial Correction of "Financial Summary Supplementary Materials - Fiscal Year Ending December 2025 -"
Partial corrections were made in the supplementary financial summary for the fiscal year ending December 2025 regarding consolidated results, capital investment and intangible asset investment amounts, and product- and region-specific revenues.
Read more -
Notice Regarding Partial Amendments to the Articles of Incorporation
Kyowa Kirin Co., Ltd. plans to propose partial amendments to the Articles of Incorporation at the Annual General Meeting of Shareholders scheduled for March 19, 2026, aimed at adding new business purposes and transitioning to a company with an audit...
Read more -
Financial Summary for the Fiscal Year Ending December 2025 [IFRS] (Consolidated)
For the fiscal year ending December 2025, revenue was JPY 496.8 billion (0.3% YoY increase), net income attributable to owners of parent was JPY 67.0 billion (12.0% YoY increase). For the fiscal year ending December 2026, revenue is projected at...
Read more -
Financial Summary Supplemental Material – Fiscal Year Ending December 2025 –
For the fiscal year ending December 2025, revenue was 496.8 billion yen, flat year-over-year, core operating income was 127.9 billion yen, down 4% year-over-year, and net income attributable to owners of parent was 67.0 billion yen, up 12% year-over-year.
Read more -
Notice Regarding Change in Dividend Policy (DOE and Progressive Dividend)
Kyowa Kirin Co., Ltd. will change its dividend policy from a core EPS payout ratio of 40% to a DOE of 4% or more with a progressive dividend starting from the fiscal year ending December 2026, with the dividend for...
Read more
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥2,682
Rating Score: 2.45 (Based on 10 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Kyowa Kirin Co., Ltd. engages in the research, development, manufacture, import/export, and market of pharmaceuticals products worldwide. The company offers Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; POTELIGEO for the treatment of cutaneous T-cell lymphoma; Nouriast/Nourianz, an adenosine A2A receptor antagonist; G-LASTA, a mobilization of hematopoietic stem cells into peripheral blood for autologous blood stem cell transplantation; Libmeldy/Lenmeldy for treating metachromatic leukodystrophy; Orkedia for treatment of secondary hyperparathyroidism; and Romiplate to treat aplastic anemia. It also develops OTL-203 for the treatment of mucopolysaccharidosis type IH (hurler syndrome); KHK4083/AMG 451 to treat atopic dermatitis, prurigo nodularis, and asthma; OTL-201 for the treatment of mucopolysaccharidosis type IIIA (sanfilippo syndrome type A); ziftomenib for treating R/R acute myeloid Leukemia and acute lymphoblastic leukemia; KHK4951 for the treatment of diabetic macular edema and neovascular age-related macular degeneration; KK8123 to treat x-linked hypophosphatemia; KK2845 for the treatment of acute myeloid leukemia; KK4277 for treating systemic and cutaneous lupus erythematosus; Lumicef to treat palmoplantar pustulosis; KK2260 and KK2269 for the treatment of solid tumors; and KK8398 for the treatment of achondroplasia. The company has a strategic research collaboration with Kirin Holdings Company, Limited and Metagen, Inc. to develop new test items based on gut microbiota data. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
